Breakthrough technology solves issues in production of life-saving treatment for blood cancer

Researchers have developed a new technique to enhance CAR T-cell therapy for blood cancers, addressing manufacturing bottlenecks.

Researchers from the University of South Australia have developed a new technique using inertial microfluidics to enhance CAR T-cell therapy for leukemia and other blood cancers.
CAR T-cell therapy involves reprogramming immune cells from a cancer patient to attack the tumor and has shown effectiveness in treating aggressive lymphomas.
The microfluidic technology efficiently removes contaminating cancerous cells and large white blood cells, improving the purity and effectiveness of the CAR T-cell manufacturing process.
The disposable devices used with the inertial spiral microfluidics are cost-effective and easily integrated into current processes, potentially reducing costs by up to 14%.
Clinical trials are planned to further validate the technology, with the goal of making CAR T-cell therapy more efficient, accessible, and cost-effective for cancer patients.

FDA gives green light to new drug for certain type of thyroid cancer